The proposal ’ExoSens-PoC: Enhancing tests for the early diagnosis of Alzheimer’s disease‘ been granted by MICINN (Proyectos de «Prueba de Concepto» 2022 Call). ExoSens-PoC proposal addresses the development of a Proof-of-Concept/Point-of- Care (PoC) test for the early identification of individuals at risk of AD in plasma. This approach can efficiently and specifically separate exosomes from neuronal origin by magnetic separation using antibodies directed against proteins enriched in neuron-derived exosome (L1CAM) or AD-related biomarkers (BACE1). The team is formed by Prof. Isabel Pividori (IP) and Mercè Martí (UAB), Dra. Amanda Cano (ACE foundation/ Institut Català de Neurociències Aplicades, and EureCat (outsourcing for the prototyping of the platform).